Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities

R Cannalire, C Cerchia, AR Beccari… - Journal of medicinal …, 2020 - ACS Publications
The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …

The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2

Z Jin, H Wang, Y Duan, H Yang - Biochemical and Biophysical Research …, 2021 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented global health …

Targeting SARS-CoV-2 proteases for COVID-19 antiviral development

Z Lv, KE Cano, L Jia, M Drag, TT Huang… - Frontiers in …, 2022 - frontiersin.org
The emergence of severe acute respiratory syndrome (SARS-CoV-2) in 2019 marked the
third occurrence of a highly pathogenic coronavirus in the human population since 2003. As …

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

I Vicenti, M Zazzi, F Saladini - Expert Opinion on Therapeutic …, 2021 - Taylor & Francis
ABSTRACT Introduction: The current SARS-CoV-2 pandemic urgently demands for both
prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has …

[HTML][HTML] Structural similarity of SARS-CoV2 Mpro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics

K Bafna, RM Krug, GT Montelione - ChemRxiv, 2020 - ncbi.nlm.nih.gov
During the current COVID-19 pandemic more than 160,000 people have died worldwide as
of mid-April 2020, and the global economy has been crippled. Effective control of the SARS …

[HTML][HTML] Inhibitors of sars-cov-2 plpro

DJ Calleja, G Lessene, D Komander - Frontiers in Chemistry, 2022 - frontiersin.org
The emergence of SARS-CoV-2 causing the COVID-19 pandemic, has highlighted how a
combination of urgency, collaboration and building on existing research can enable rapid …

Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2

CJ Kuo, TL Chao, HC Kao, YM Tsai… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
ABSTRACT Coronavirus (CoV) disease 2019 (COVID-19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed many lives worldwide and …

Viral proteases as targets for coronavirus disease 2019 drug development

W Zhu, Z Shyr, DC Lo, W Zheng - Journal of Pharmacology and …, 2021 - ASPET
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), continues to be a global threat since its emergence. Although …

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

Progress and challenges in targeting the SARS-CoV-2 papain-like protease

H Tan, Y Hu, P Jadhav, B Tan… - Journal of medicinal …, 2022 - ACS Publications
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …